Aniridia-Net and Aniridia Europe are happy to announce this new webinar which will take place on May 20th at 1PM CEST and will talk about orphan medicinal products, recommended to an audience of professionals working in the field of aniridia and the other rare diseases.

There are currently more than 30 million people in the European Union affected by one of the more than 6,000 rare diseases identified to date. There are very few medicines intended for the treatment of rare diseases. To foster development in this area, the European Union’s orphan medicines legislation, launched in the year 2000, supports and promotes, through an incentive-based system, the development of quality, safe and effective medicines to treat these diseases. These are the orphan medicines. The incentives included in the orphan medicines regulation seek to encourage the development of products that would not otherwise be developed without this support. Medicines eligible to benefit from these incentives are identified through the orphan designation procedure, which is performed by the Committee for Orphan Medicinal Products (COMP), the scientific committee of the European Medicines Agency (EMA) responsible for recommendations on orphan medicinal products.

In this webinar we will walk through the orphan designation process, from the first steps of initial designation to the last phase of maintenance at the time of marketing authorization application.

The speaker, Gloria M. Palomo, holds a BsC in Biochemistry and is an enthusiast of Neuroscience and Molecular Biology, which were the topics followed in her postgraduate studies. During her PhD studies at Universidad Autónoma de Madrid, Gloria focused her work on a rare neurodegenerative disease, Friedreich´s ataxia, where she uncovered a new mechanism underlying neuronal cell death and contributed to the proof of concept studies for the gene therapy in this disease. During her postdoc at Weill Cornell Medicine in New York, she worked on ALS and the pathological mechanisms of the disease associated with mitochondria quality control, especially mitophagy. Gloria M. Palomo is currently non-clinical assessor in the Vaccines and Advanced Therapies Service at the Spanish Agency for Medicinal Products and Medical Devices, and the member from Spain of the Committee for Orphan Medicinal Products of EMA.

Please, find below the link to follow the webinar. No registration is needed.

Click here to join the webinar!



About Aniridia-Net: Funded by the Horizon 2020 Framework Programme of the European Union. This activity is based upon the work from COST Action ANIRIDIA-NET #CA18116 and supported by COST.
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks aiming to connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers.